Potent And Orally Bioavailable Cdk8 Inhibitors Design Synthesis Herein we detail the discovery of a series of novel pyridine derived cdk8 inhibitors. medicinal chemistry optimisation gave rise to 38 (au1 100), a potent cdk8 inhibitor with oral bioavailability. the compound inhibited the proliferation of mv4 11 acute myeloid leukaemia cells with the kinase activity of cellular cdk8 dampened. Cdk8 regulates transcription either by phosphorylation of transcription factors or, as part of a four subunit kinase module, through a reversible association of the kinase module with the mediator complex, a highly conserved transcriptional coactivator.
Figure 3 From Design And Synthesis Of Orally Bioavailable Piperazine Compound 109 (cct251921), a potent, selective, and orally bioavailable inhibitor of cdk8 with equipotent affinity for cdk19 is reported, which affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer. Cyclin dependent kinase 8 (cdk8), as a kinase subunit of the mediator complex, is involved in the regulation of rna polymerase ii mediated transcription, thereby modulating multiple signaling pathways and multiple transcription factors involved in oncogenic control. cdk8 deregulation has been implicated in human diseases, particularly in acute myeloid leukemia (aml) and advanced solid tumors. Request pdf | potent and orally bioavailable cdk8 inhibitors: design, synthesis, structure activity relationship analysis and biological evaluation | cdk8 regulates transcription either by. Thus, the synergistic effects of stat inhibitor with cdk8 inhibitor could provide new therapeutic opportunities for aml, rather than reverse the effects of the cdk8 inhibitor. based on the previous work, a total of 40 compounds were designed and synthesised through rational design and discussion on structure activity relationships.
Comments are closed.